Published: May 14, 2021 By Brandon May
Foresite Labs-incubated company Interline Therapeutics
announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners. The funding, which has officially launched the company, will be geared toward the development of therapies that correct dysfunctional protein communities to treat various diseases.
The $92 million financing round is a combination of seed and Series A funding. The newly launched company says the proceeds will be funneled to facilitate the expansion of its research platform and advance a total of six preclinical therapeutic programs.
Interline Therapeutics will specifically use genomics, proteomics, structural biology, and computational chemistry to “map and modulate protein communities” to construct a precision medicine platform focused on genomics, protein communities, and modulators of these communities. These three pillars form the basis of
Interline Therapeutics Raises $92M in Funding
The round was led by Foresite Capital and ARCH Venture Partners.
The company intends to use the funds to expand the research platform and advance six preclinical therapeutic programs.
Co-founded by CEO Zachary Sweeney, Interline Therapeutics is a Foresite Labs incubated company that focuses on systematically elucidating protein communities to define molecular mechanisms of disease.
The company uses genomics, proteomics, structural biology and computational chemistry to systematically map and modulate protein communities. Interline Therapeutics is leveraging recent advancements in these technologies, as well as collaborations with academic groups, to develop a precision medicine platform focused on three essential areas: